IL25514A - Therapeutic compositions for the prevention of anaphylactic shock containing beta-(2-pyridyl-lower alkyl)amines or beta-(4-pyridyl-lower alkyl)amines - Google Patents
Therapeutic compositions for the prevention of anaphylactic shock containing beta-(2-pyridyl-lower alkyl)amines or beta-(4-pyridyl-lower alkyl)aminesInfo
- Publication number
- IL25514A IL25514A IL2551466A IL2551466A IL25514A IL 25514 A IL25514 A IL 25514A IL 2551466 A IL2551466 A IL 2551466A IL 2551466 A IL2551466 A IL 2551466A IL 25514 A IL25514 A IL 25514A
- Authority
- IL
- Israel
- Prior art keywords
- anaphylactic shock
- allergic
- amines
- pyridyl
- lower alkyl
- Prior art date
Links
- 208000003455 anaphylaxis Diseases 0.000 title claims description 24
- 206010002199 Anaphylactic shock Diseases 0.000 title claims description 22
- 239000000203 mixture Substances 0.000 title claims description 22
- 230000001225 therapeutic effect Effects 0.000 title claims description 14
- 150000001412 amines Chemical class 0.000 title claims description 6
- 125000000217 alkyl group Chemical group 0.000 title description 8
- 230000002265 prevention Effects 0.000 title description 4
- 230000000172 allergic effect Effects 0.000 claims description 15
- 208000010668 atopic eczema Diseases 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 229960003223 tripelennamine Drugs 0.000 claims 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 claims 1
- 229960001128 triprolidine Drugs 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 description 17
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 16
- 229940049954 penicillin Drugs 0.000 description 16
- 230000001235 sensitizing effect Effects 0.000 description 11
- 230000002052 anaphylactic effect Effects 0.000 description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000035939 shock Effects 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010027654 Allergic conditions Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- RAUYIDQLJZIDDD-UHFFFAOYSA-N diphenyl-$l^{3}-chlorane Chemical compound C=1C=CC=CC=1[ClH]C1=CC=CC=C1 RAUYIDQLJZIDDD-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- UMSVPCYSAUKCAZ-UHFFFAOYSA-N propane;hydrochloride Chemical compound Cl.CCC UMSVPCYSAUKCAZ-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45496765A | 1965-05-11 | 1965-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL25514A true IL25514A (en) | 1970-05-21 |
Family
ID=23806815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL2551466A IL25514A (en) | 1965-05-11 | 1966-04-01 | Therapeutic compositions for the prevention of anaphylactic shock containing beta-(2-pyridyl-lower alkyl)amines or beta-(4-pyridyl-lower alkyl)amines |
Country Status (4)
| Country | Link |
|---|---|
| ES (1) | ES326590A1 (enrdf_load_html_response) |
| FR (1) | FR6204M (enrdf_load_html_response) |
| GB (1) | GB1103135A (enrdf_load_html_response) |
| IL (1) | IL25514A (enrdf_load_html_response) |
-
1966
- 1966-04-01 IL IL2551466A patent/IL25514A/en unknown
- 1966-04-04 GB GB14934/66A patent/GB1103135A/en not_active Expired
- 1966-05-11 ES ES0326590A patent/ES326590A1/es not_active Expired
- 1966-06-06 FR FR61017A patent/FR6204M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR6204M (enrdf_load_html_response) | 1968-07-29 |
| GB1103135A (en) | 1968-02-14 |
| ES326590A1 (es) | 1967-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Day et al. | The pharmacology of local anesthetics | |
| US4656034A (en) | Absorption enhancing agents | |
| EP0139534B1 (en) | Compositions for the prophylactic treatment of osteitis and osteomyelitis | |
| Groban et al. | Lipid reversal of bupivacaine toxicity: has the silver bullet been identified? | |
| Smith et al. | Iron‐chelating agents for treating malaria | |
| Lowe et al. | Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis: efficacy and duration with repeated treatments | |
| US3063901A (en) | Composition and method for treating anticholinesterase poisoning | |
| EP0192660B1 (en) | Absorption enhancing agents | |
| Kingstone | The lithium treatment of hypomanic and manic states | |
| IL25514A (en) | Therapeutic compositions for the prevention of anaphylactic shock containing beta-(2-pyridyl-lower alkyl)amines or beta-(4-pyridyl-lower alkyl)amines | |
| Friedlaender et al. | Histamine antagonists. V. Comparison of benadryl and pyribenzamine in histamine and anaphylactic shock | |
| AU7099194A (en) | Methods and compositions for lowering intraocular pressure | |
| Foster et al. | Comparative studies of the action of mirasan, lucanthone, hycanthone and niridazole against Schistosoma mansoni in mice | |
| Bowman* et al. | Canine filariasis (Heartworm)–disease and current gaps | |
| O'Donnell et al. | Inhibition of enterotoxin-induced porcine colonic secretion by diarylsulfonylureas in vitro | |
| US4017614A (en) | Compositions for the relief of migraine | |
| US3873709A (en) | Method of treating psychosis | |
| Roy et al. | A comparison of controlled release metoclopramide and domperidone in the treatment of nausea and vomiting | |
| RU2077326C1 (ru) | Препарат для анальгезии | |
| Aapro et al. | Antiemetic efficacy of droperidol or metoclopramide combined with dexamethasone and diphenhydramine: randomized open parallel study | |
| Feldberg et al. | Effects of monoamine oxidase inhibitors and amphetamine on hypothermia produced by halothane | |
| Raffel et al. | The Influence of Ascorbic Acid on Anaphylaxis in Guinea Pigs | |
| Feinberg et al. | Histamine antagonists: X. A new antihistaminic drug, 2-[α-(2-dimethylaminoethoxy)-α-methylbenzyl]-pyridine succinate (Decapryn succinate); experimental and clinical results | |
| CA1209047A (en) | Therapeutic composition containing piracetam analog | |
| Sakamoto et al. | The mechanism of Ptychodiscus brevis toxin-induced rat vas deferens contraction |